|
|
| | HTH-01-091 Basic information |
| Product Name: | HTH-01-091 | | Synonyms: | HTH-01-091;HTH 01 091,HTH01091;Pyrimido[5,4-c]quinolin-2(1H)-one, 9-(3,5-dichloro-4-hydroxyphenyl)-1-[trans-4-[(dimethylamino)methyl]cyclohexyl]-3,4-dihydro-;HTH-01-091, 10 mM in DMSO | | CAS: | 2000209-42-5 | | MF: | C26H28Cl2N4O2 | | MW: | 499.43 | | EINECS: | | | Product Categories: | | | Mol File: | 2000209-42-5.mol |  |
| | HTH-01-091 Chemical Properties |
| Boiling point | 679.4±55.0 °C(Predicted) | | density | 1.327±0.06 g/cm3(Predicted) | | pka | 6.16±0.25(Predicted) | | form | Solid | | color | White to light yellow |
| | HTH-01-091 Usage And Synthesis |
| Description | HTH-01-091 is a selective maternal embryonic leucine zipper kinase (MELK) inhibitor. HTH-01-091 provides a general framework for preclinical target validation. | | Uses | HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC50 of 10.5 nM. HTH-01-091 also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 can be uesd for breast cancer research[1]. | | IC 50 | DYRK4: 41.8 nM (IC50); RIPK2; PIM1: 60.6 nM (IC50); mTOR: 632 nM (IC50); CDK7: 1230 nM (IC50); PIM2; PIM3 | | References | [1] Huang HT, et al. MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 2017 Sep 19;6:e26693. DOI:10.7554/eLife.26693 |
| | HTH-01-091 Preparation Products And Raw materials |
|